Equities Analysts Issue Forecasts for Tocagen’s Q2 2018 Earnings (TOCA)

Tocagen (NASDAQ:TOCA) – Stock analysts at B. Riley issued their Q2 2018 earnings estimates for shares of Tocagen in a research note issued to investors on Wednesday, May 16th. B. Riley analyst M. Kumar expects that the company will earn ($0.63) per share for the quarter. B. Riley currently has a “Buy” rating and a $15.00 target price on the stock. B. Riley also issued estimates for Tocagen’s Q3 2018 earnings at $0.17 EPS, Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.56) EPS, Q1 2019 earnings at ($0.74) EPS, Q2 2019 earnings at ($0.71) EPS, Q3 2019 earnings at ($0.68) EPS, Q4 2019 earnings at ($0.65) EPS and FY2019 earnings at ($2.61) EPS.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.65) EPS for the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. The company had revenue of $0.01 million during the quarter.

Other analysts have also issued reports about the stock. BidaskClub upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Saturday, March 17th. Zacks Investment Research upgraded shares of Tocagen from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Wednesday, March 14th. Finally, ValuEngine upgraded shares of Tocagen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $16.67.

Shares of TOCA stock opened at $9.90 on Friday. Tocagen has a 52 week low of $9.57 and a 52 week high of $9.76. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.56 and a quick ratio of 5.23.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Tocagen by 36.4% during the fourth quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock valued at $10,960,000 after buying an additional 285,396 shares during the period. Lake Street Advisors Group LLC bought a new stake in Tocagen during the fourth quarter valued at approximately $1,042,000. Artal Group S.A. bought a new stake in Tocagen during the fourth quarter valued at approximately $1,025,000. Geode Capital Management LLC grew its position in Tocagen by 16.0% during the fourth quarter. Geode Capital Management LLC now owns 90,452 shares of the company’s stock valued at $927,000 after buying an additional 12,472 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Tocagen by 107.4% during the first quarter. Russell Investments Group Ltd. now owns 81,067 shares of the company’s stock valued at $961,000 after buying an additional 41,978 shares during the period. Institutional investors own 32.48% of the company’s stock.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Earnings History and Estimates for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply